(NASDAQ: ELOX) Eloxx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.74%.
Eloxx Pharmaceuticals's earnings in 2026 is N/A.On average, 4 Wall Street analysts forecast ELOX's earnings for 2026 to be -$10,951,721, with the lowest ELOX earnings forecast at -$11,273,830, and the highest ELOX earnings forecast at -$10,468,556. On average, 4 Wall Street analysts forecast ELOX's earnings for 2027 to be -$11,198,752, with the lowest ELOX earnings forecast at -$14,280,185, and the highest ELOX earnings forecast at -$7,756,056.
In 2028, ELOX is forecast to generate -$10,560,588 in earnings, with the lowest earnings forecast at -$12,183,648 and the highest earnings forecast at -$8,688,478.